Abstract
In the United States, there has been an increase in anticoagulation or anti-platelet agents in the geriatric population. This demographic is also at risk for falls or other blunt trauma, resulting in significant post-injury bleeding. The best management strategy for anti-platelet-related bleeding is still under debate. Preliminary data suggest that the incidence of clinically significant intracranial hemorrhage is significantly lower with NOAC/DOACs than with anti-Vitamin K anticoagulants. Nonetheless, the risk of bleeding is still present.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
